研究单位：[1]Xuanwu Hospital of Capital Medical University,Beijing,China[2]Shanghai IxCell Biotechnology Co., LTD
研究目的：
To evaluate the safety and tolerability of IxCellhUC-MSC-S as a single intravenous infusion in convalescent patients with ischemic stroke. To explore the efficacy of IxCellhUC-MSC-S as a single intravenous infusion in patients with convalescent ischemic stroke.
